New
Published today. Thirty six PubMed records were found by our Chief Scientific Director Dr. Korobko to be relevant and of interest, and were included into this quarterly overview. The review includes sections on epidemiology, comorbidities, quality of life, vitiligo triggers, new case reports, new clinical studies and trials, analysis of mechanisms of vitiligo pathogenesis, genetic studies, candidate biomarkers, mechanisms of treatments, methodological advancements and novel treatment modalities.
FAQOther Questions
- Will it spread?
Vitiligo's progression and response to treatment can vary significantly among individuals, making it a particularly unpredictable skin condition. Based on the VALIANT study, her...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Shall I try low-fat diet for my vitiligo?
The link between dietary fat and autoimmune diseases like vitiligo is a compelling yet complex puzzle that continues to intrigue scientists. While the conversation is ongoing, o...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.